Details for Patent: 10,383,876
✉ Email this page to a colleague
Which drugs does patent 10,383,876 protect, and when does it expire?
Patent 10,383,876 protects ALIQOPA and is included in one NDA.
This patent has fifty-three patent family members in forty-two countries.
Summary for Patent: 10,383,876
Title: | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
Abstract: | The present invention relates:--to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-- c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): or a tautomer, solvate or hydrate thereof;--to methods of preparing said dihydrochloride salt;--to said dihydrochloride salt for the treatment and/or prophylaxis of a disease;--to the use of said dihydrochloride salt for the preparation of a medicament for the treatment and/or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, more particularly for the treatment or prophylaxis of a cancer, particularly lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, hepatocyte carcinoma, pancreatic cancer, hepatocyte carcinoma or breast cancer;--to a pharmaceutical composition comprising said dihydrochloride salt; and--to a pharmaceutical combination comprising said dihydrochloride salt in combination with one or more further pharmaceutical agents. ##STR00001## |
Inventor(s): | Peters; Jan-Georg (Solingen, DE), Militzer; Hans-Christian (Odenthal, DE), Muller; Hartwig (Velbert, DE) |
Assignee: | BAYER INTELLECTUAL PROPERTY GMBH (Monheim, DE) |
Application Number: | 14/009,599 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; Delivery; |
Drugs Protected by US Patent 10,383,876
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Healthcare | ALIQOPA | copanlisib dihydrochloride | POWDER;INTRAVENOUS | 209936-001 | Sep 14, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,383,876
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
11161111 | Apr 5, 2011 |
PCT Information | |||
PCT Filed | March 29, 2012 | PCT Application Number: | PCT/EP2012/055600 |
PCT Publication Date: | October 11, 2012 | PCT Publication Number: | WO2012/136553 |
International Family Members for US Patent 10,383,876
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
African Regional IP Organization (ARIPO) | 3709 | ⤷ Try a Trial | |||
Argentina | 085718 | ⤷ Try a Trial | |||
Australia | 2012238891 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |